{
  "metadata": {
    "graph_path": "./logic_graph.png",
    "num_solutions": 9,
    "family_stats": {
      "1": {
        "core": 1,
        "branch": 0
      },
      "2": {
        "core": 1,
        "branch": 0
      },
      "3": {
        "core": 1,
        "branch": 0
      },
      "4": {
        "core": 1,
        "branch": 1
      },
      "5": {
        "core": 1,
        "branch": 3
      }
    }
  },
  "knowledge_base": {
    "rules": [
      {
        "id": "Rule1",
        "formal": "(A11 ∨ A12)",
        "prover9_expression": "(safety_issue_reported(CompoundX) | adverse_event_study(CompoundX))",
        "natural": "Either a safety issue for CompoundX was reported, or an adverse event study was conducted on CompoundX."
      },
      {
        "id": "Rule2",
        "formal": "(A12 → (A10 → A9))",
        "prover9_expression": "(adverse_event_study(CompoundX) -> (generic_available(CompoundX) -> patent_expired(CompoundX)))",
        "natural": "Should an adverse event study have been conducted on CompoundX, then it is the case that the availability of a generic version implies the patent for CompoundX has expired."
      },
      {
        "id": "Rule3",
        "formal": "(A13 → (A10 → A9))",
        "prover9_expression": "(fda_investigation(CompoundX) -> (generic_available(CompoundX) -> patent_expired(CompoundX)))",
        "natural": "If the FDA is investigating CompoundX, then the availability of a generic version necessitates that the patent for CompoundX has expired."
      },
      {
        "id": "Rule4",
        "formal": "(A15 → ¬A14)",
        "prover9_expression": "(recall_order_issued(CompoundX) -> -product_recall(CompoundX))",
        "natural": "Provided that a recall order was issued for CompoundX, it is not the case that a product recall occurred for CompoundX."
      },
      {
        "id": "Rule5",
        "formal": "(A16 → A18)",
        "prover9_expression": "(new_formulation(CompoundX) -> extended_release(CompoundX))",
        "natural": "If a new formulation of CompoundX exists, then CompoundX has an extended release mechanism."
      },
      {
        "id": "Rule6",
        "formal": "(A17 → G)",
        "prover9_expression": "(improved_bioavailability(CompoundX) -> product_on_market(CompoundX))",
        "natural": "Should CompoundX have improved bioavailability, then CompoundX is on the market."
      },
      {
        "id": "Rule7",
        "formal": "(A18 → A19)",
        "prover9_expression": "(extended_release(CompoundX) -> reduced_dosing(CompoundX))",
        "natural": "If CompoundX has an extended release mechanism, then CompoundX dosing has been reduced."
      },
      {
        "id": "Rule8",
        "formal": "(A19 → A17)",
        "prover9_expression": "(reduced_dosing(CompoundX) -> improved_bioavailability(CompoundX))",
        "natural": "Under the condition that CompoundX dosing has been reduced, CompoundX has improved bioavailability."
      },
      {
        "id": "Rule9",
        "formal": "(A2 → A3)",
        "prover9_expression": "(developed_by(CompoundX, LabAlpha) -> patented(CompoundX))",
        "natural": "If CompoundX was developed by LabAlpha, then CompoundX is patented."
      },
      {
        "id": "Rule10",
        "formal": "(A20 → G)",
        "prover9_expression": "(manufacturing_upgrade(CompoundX) -> product_on_market(CompoundX))",
        "natural": "Whenever a manufacturing upgrade was performed for CompoundX, CompoundX is on the market."
      },
      {
        "id": "Rule11",
        "formal": "(A21 → G)",
        "prover9_expression": "(gmp_compliance(CompoundX) -> product_on_market(CompoundX))",
        "natural": "Should CompoundX be compliant with Good Manufacturing Practices (GMP), then CompoundX is on the market."
      },
      {
        "id": "Rule12",
        "formal": "(A22 → A20)",
        "prover9_expression": "(equipment_modernization(CompoundX) -> manufacturing_upgrade(CompoundX))",
        "natural": "Under the condition that equipment modernization was undertaken for CompoundX, a manufacturing upgrade was performed for CompoundX."
      },
      {
        "id": "Rule13",
        "formal": "(A22 ∨ A23)",
        "prover9_expression": "(equipment_modernization(CompoundX) | process_automation(CompoundX))",
        "natural": "Either equipment modernization was undertaken for CompoundX, or process automation was implemented for CompoundX."
      },
      {
        "id": "Rule14",
        "formal": "(A23 → A24)",
        "prover9_expression": "(process_automation(CompoundX) -> quality_control_system(CompoundX))",
        "natural": "If process automation was implemented for CompoundX, then a quality control system is in place for CompoundX."
      },
      {
        "id": "Rule15",
        "formal": "(A27 → A28)",
        "prover9_expression": "(supply_chain_disruption(CompoundX) -> raw_material_shortage(CompoundX))",
        "natural": "Provided that a supply chain disruption affected CompoundX, a raw material shortage affected CompoundX."
      },
      {
        "id": "Rule16",
        "formal": "(A3 → A4)",
        "prover9_expression": "(patented(CompoundX) -> clinical_trial_success(CompoundX))",
        "natural": "If CompoundX is patented, then CompoundX had a successful clinical trial."
      },
      {
        "id": "Rule17",
        "formal": "(A30 ∨ (A29 ∨ (A28 → (¬G → A26))))",
        "prover9_expression": "(import_license_secured(CompoundX) | (alternative_supplier_found(CompoundX) | (raw_material_shortage(CompoundX) -> (-product_on_market(CompoundX) -> production_delay(CompoundX)))))",
        "natural": "Either an import license was secured for CompoundX, or an alternative supplier was found, or a raw material shortage leads to a production delay when the product is not on the market."
      },
      {
        "id": "Rule18",
        "formal": "(A31 → A21)",
        "prover9_expression": "(batch_tracking_system(CompoundX) -> gmp_compliance(CompoundX))",
        "natural": "Under the condition that a batch tracking system is in place for CompoundX, CompoundX is compliant with Good Manufacturing Practices (GMP)."
      },
      {
        "id": "Rule19",
        "formal": "(A32 → (A23 → A31))",
        "prover9_expression": "(software_implementation(CompoundX) -> (process_automation(CompoundX) -> batch_tracking_system(CompoundX)))",
        "natural": "Provided that software was implemented for CompoundX, then the implementation of process automation necessitates that a batch tracking system is in place."
      },
      {
        "id": "Rule20",
        "formal": "(A33 → (A23 → A31))",
        "prover9_expression": "(hardware_installation(CompoundX) -> (process_automation(CompoundX) -> batch_tracking_system(CompoundX)))",
        "natural": "Should hardware be installed for CompoundX, then the implementation of process automation implies a batch tracking system is in place."
      },
      {
        "id": "Rule21",
        "formal": "(A34 → A35)",
        "prover9_expression": "(system_integration_failure(CompoundX) -> data_corruption(CompoundX))",
        "natural": "Whenever a system integration failure occurred for CompoundX, data corruption occurred for CompoundX."
      },
      {
        "id": "Rule22",
        "formal": "(A36 → ¬A35)",
        "prover9_expression": "(validation_error(CompoundX) -> -data_corruption(CompoundX))",
        "natural": "Under the condition that a validation error occurred for CompoundX, data corruption did not occur for CompoundX."
      },
      {
        "id": "Rule23",
        "formal": "(A39 → (A38 ∨ (A27 → (¬G → A26))))",
        "prover9_expression": "(contingency_plan_activated(CompoundX) -> (backup_supplier_available(CompoundX) | (supply_chain_disruption(CompoundX) -> (-product_on_market(CompoundX) -> production_delay(CompoundX)))))",
        "natural": "Should a contingency plan be activated for CompoundX, then either a backup supplier is available, or a supply chain disruption leads to a production delay if the product is not on the market."
      },
      {
        "id": "Rule24",
        "formal": "(A40 → (A38 ∨ (A27 → (¬G → A26))))",
        "prover9_expression": "(emergency_protocol_executed(CompoundX) -> (backup_supplier_available(CompoundX) | (supply_chain_disruption(CompoundX) -> (-product_on_market(CompoundX) -> production_delay(CompoundX)))))",
        "natural": "If an emergency protocol was executed for CompoundX, then either a backup supplier is available, or a supply chain disruption necessitates a production delay when the product is not on the market."
      },
      {
        "id": "Rule25",
        "formal": "(A41 → A43)",
        "prover9_expression": "(crisis_management_team(CompoundX) -> management_approval(CompoundX))",
        "natural": "Should a crisis management team be formed for CompoundX, management approval was obtained for CompoundX."
      },
      {
        "id": "Rule26",
        "formal": "(A41 ∨ A42)",
        "prover9_expression": "(crisis_management_team(CompoundX) | emergency_response_unit(CompoundX))",
        "natural": "Either a crisis management team was formed for CompoundX, or an emergency response unit was deployed for CompoundX."
      },
      {
        "id": "Rule27",
        "formal": "(A42 → A40)",
        "prover9_expression": "(emergency_response_unit(CompoundX) -> emergency_protocol_executed(CompoundX))",
        "natural": "Provided that an emergency response unit was deployed for CompoundX, an emergency protocol was executed for CompoundX."
      },
      {
        "id": "Rule28",
        "formal": "(A44 → A39)",
        "prover9_expression": "(board_authorization(CompoundX) -> contingency_plan_activated(CompoundX))",
        "natural": "Under the condition that board authorization was obtained for CompoundX, a contingency plan was activated for CompoundX."
      },
      {
        "id": "Rule29",
        "formal": "(A48 → A26)",
        "prover9_expression": "(production_rescheduled(CompoundX) -> production_delay(CompoundX))",
        "natural": "Should production of CompoundX be rescheduled, then production of CompoundX was delayed."
      },
      {
        "id": "Rule30",
        "formal": "(A49 → A48)",
        "prover9_expression": "(timeline_adjusted(CompoundX) -> production_rescheduled(CompoundX))",
        "natural": "Provided that the timeline for CompoundX was adjusted, production of CompoundX was rescheduled."
      },
      {
        "id": "Rule31",
        "formal": "(A51 → A50)",
        "prover9_expression": "(process_validation_complete(CompoundX) -> alternative_process_available(CompoundX))",
        "natural": "If process validation is complete for CompoundX, then an alternative process is available for CompoundX."
      },
      {
        "id": "Rule32",
        "formal": "(A51 ∨ A52)",
        "prover9_expression": "(process_validation_complete(CompoundX) | manual_override_authorized(CompoundX))",
        "natural": "Either process validation is complete for CompoundX, or a manual override was authorized for CompoundX."
      },
      {
        "id": "Rule33",
        "formal": "(A52 → A53)",
        "prover9_expression": "(manual_override_authorized(CompoundX) -> supervisor_approval(CompoundX))",
        "natural": "Provided that a manual override was authorized for CompoundX, supervisor approval was obtained for CompoundX."
      },
      {
        "id": "Rule34",
        "formal": "(A6 ∨ ¬A5)",
        "prover9_expression": "(market_withdrawal(CompoundX) | -regulatory_rejection(CompoundX))",
        "natural": "Either CompoundX was withdrawn from the market, or it is not the case that CompoundX received a regulatory rejection."
      },
      {
        "id": "Rule35",
        "formal": "(A7 ∨ ¬A6)",
        "prover9_expression": "(production_halt(CompoundX) | -market_withdrawal(CompoundX))",
        "natural": "Either production of CompoundX was halted, or CompoundX was not withdrawn from the market."
      },
      {
        "id": "Rule36",
        "formal": "(A8 → G)",
        "prover9_expression": "(manufacturing_license_granted(CompoundX) -> product_on_market(CompoundX))",
        "natural": "If a manufacturing license was granted for CompoundX, then CompoundX is on the market."
      },
      {
        "id": "Rule37",
        "formal": "(¬(A11 → A13) → A14)",
        "prover9_expression": "(-(safety_issue_reported(CompoundX) -> fda_investigation(CompoundX)) -> product_recall(CompoundX))",
        "natural": "If it is not the case that a reported safety issue leads to an FDA investigation, then a product recall occurred for CompoundX."
      },
      {
        "id": "Rule38",
        "formal": "(¬(A24 → A21) → A25)",
        "prover9_expression": "(-(quality_control_system(CompoundX) -> gmp_compliance(CompoundX)) -> compliance_failure(CompoundX))",
        "natural": "Provided that it is false that a quality control system implies GMP compliance, then a compliance failure occurred for CompoundX."
      },
      {
        "id": "Rule39",
        "formal": "(¬(A32 ∨ A33) → A34)",
        "prover9_expression": "(-(software_implementation(CompoundX) | hardware_installation(CompoundX)) -> system_integration_failure(CompoundX))",
        "natural": "Under the condition that neither software was implemented nor hardware was installed for CompoundX, a system integration failure occurred for CompoundX."
      },
      {
        "id": "Rule40",
        "formal": "(¬(A34 → A36) → A37)",
        "prover9_expression": "(-(system_integration_failure(CompoundX) -> validation_error(CompoundX)) -> validation_success(CompoundX))",
        "natural": "If it is not the case that a system integration failure leads to a validation error, then validation was successful for CompoundX."
      },
      {
        "id": "Rule41",
        "formal": "(¬(A34 → A36) → ¬A37)",
        "prover9_expression": "(-(system_integration_failure(CompoundX) -> validation_error(CompoundX)) -> -validation_success(CompoundX))",
        "natural": "Should it be false that a system integration failure necessitates a validation error, then validation was not successful for CompoundX."
      },
      {
        "id": "Rule42",
        "formal": "(¬(A4 → (A1 → G)) → A5)",
        "prover9_expression": "(-(clinical_trial_success(CompoundX) -> (approved_compound(CompoundX) -> product_on_market(CompoundX))) -> regulatory_rejection(CompoundX))",
        "natural": "Whenever it is not the case that a successful clinical trial implies approval leads to the product being on the market, then CompoundX received a regulatory rejection."
      },
      {
        "id": "Rule43",
        "formal": "(¬(A43 → A44) → A45)",
        "prover9_expression": "(-(management_approval(CompoundX) -> board_authorization(CompoundX)) -> authorization_denied(CompoundX))",
        "natural": "Provided that it is false that management approval implies board authorization, then authorization was denied for CompoundX."
      },
      {
        "id": "Rule44",
        "formal": "(¬(A46 ∨ ¬A45) → A47)",
        "prover9_expression": "(-(regulatory_approval_received(CompoundX) | -authorization_denied(CompoundX)) -> approval_pending(CompoundX))",
        "natural": "If it is not the case that either regulatory approval was received or authorization was not denied, then approval is pending for CompoundX."
      },
      {
        "id": "Rule45",
        "formal": "(¬(A46 ∨ ¬A45) → ¬A47)",
        "prover9_expression": "(-(regulatory_approval_received(CompoundX) | -authorization_denied(CompoundX)) -> -approval_pending(CompoundX))",
        "natural": "Under the condition that it is false that regulatory approval was received or authorization was not denied, approval is not pending for CompoundX."
      },
      {
        "id": "Rule46",
        "formal": "(¬(A53 → (A27 → (¬G → A26))) → A54)",
        "prover9_expression": "(-(supervisor_approval(CompoundX) -> (supply_chain_disruption(CompoundX) -> (-product_on_market(CompoundX) -> production_delay(CompoundX)))) -> override_rejected(CompoundX))",
        "natural": "Should it be false that supervisor approval implies a supply chain disruption leads to a production delay when the product is not on the market, then an override was rejected for CompoundX."
      },
      {
        "id": "Rule47",
        "formal": "(¬(A53 → (A27 → (¬G → A26))) → ¬A54)",
        "prover9_expression": "(-(supervisor_approval(CompoundX) -> (supply_chain_disruption(CompoundX) -> (-product_on_market(CompoundX) -> production_delay(CompoundX)))) -> -override_rejected(CompoundX))",
        "natural": "Provided that it is not the case that supervisor approval necessitates a supply chain disruption causing a production delay without the product on the market, then an override was not rejected for CompoundX."
      },
      {
        "id": "Rule48",
        "formal": "(¬A8 → A10)",
        "prover9_expression": "(-manufacturing_license_granted(CompoundX) -> generic_available(CompoundX))",
        "natural": "If a manufacturing license was not granted for CompoundX, then a generic version of CompoundX is available."
      },
      {
        "id": "Rule49",
        "formal": "(¬G → A49)",
        "prover9_expression": "(-product_on_market(CompoundX) -> timeline_adjusted(CompoundX))",
        "natural": "Provided that CompoundX is not on the market, the timeline for CompoundX was adjusted."
      },
      {
        "id": "Rule50",
        "formal": "(¬G → ¬A26)",
        "prover9_expression": "(-product_on_market(CompoundX) -> -production_delay(CompoundX))",
        "natural": "Under the condition that CompoundX is not on the market, it is not the case that production of CompoundX was delayed."
      }
    ],
    "facts": [
      {
        "id": "Fact1",
        "formal": "A1",
        "prover9_expression": "approved_compound(CompoundX)",
        "natural": "CompoundX is an approved compound."
      },
      {
        "id": "Fact2",
        "formal": "A15",
        "prover9_expression": "recall_order_issued(CompoundX)",
        "natural": "A recall order was issued for CompoundX."
      },
      {
        "id": "Fact3",
        "formal": "A16",
        "prover9_expression": "new_formulation(CompoundX)",
        "natural": "A new formulation of CompoundX exists."
      },
      {
        "id": "Fact4",
        "formal": "A2",
        "prover9_expression": "developed_by(CompoundX, LabAlpha)",
        "natural": "CompoundX was developed by LabAlpha."
      },
      {
        "id": "Fact5",
        "formal": "A27",
        "prover9_expression": "supply_chain_disruption(CompoundX)",
        "natural": "A supply chain disruption affected CompoundX."
      },
      {
        "id": "Fact6",
        "formal": "¬A25",
        "prover9_expression": "-compliance_failure(CompoundX)",
        "natural": "A compliance failure did not occur for CompoundX."
      },
      {
        "id": "Fact7",
        "formal": "¬A29",
        "prover9_expression": "-alternative_supplier_found(CompoundX)",
        "natural": "An alternative supplier was not found for CompoundX."
      },
      {
        "id": "Fact8",
        "formal": "¬A30",
        "prover9_expression": "-import_license_secured(CompoundX)",
        "natural": "An import license was not secured for CompoundX."
      },
      {
        "id": "Fact9",
        "formal": "¬A38",
        "prover9_expression": "-backup_supplier_available(CompoundX)",
        "natural": "A backup supplier is not available for CompoundX."
      },
      {
        "id": "Fact10",
        "formal": "¬A46",
        "prover9_expression": "-regulatory_approval_received(CompoundX)",
        "natural": "Regulatory approval was not received for CompoundX."
      },
      {
        "id": "Fact11",
        "formal": "¬A50",
        "prover9_expression": "-alternative_process_available(CompoundX)",
        "natural": "An alternative process is not available for CompoundX."
      },
      {
        "id": "Fact12",
        "formal": "¬A7",
        "prover9_expression": "-production_halt(CompoundX)",
        "natural": "Production of CompoundX was not halted."
      },
      {
        "id": "Fact13",
        "formal": "¬A9",
        "prover9_expression": "-patent_expired(CompoundX)",
        "natural": "The patent for CompoundX has not expired."
      }
    ]
  },
  "target": {
    "formal": "G",
    "prover9": "G",
    "prover9_expression": "product_on_market(CompoundX)",
    "natural": "CompoundX is on the market."
  },
  "solutions": [
    {
      "id": 1,
      "family_id": 1,
      "path_type": "core",
      "branch_from": null,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "DS",
          "premises_used": [
            "(A7 | -A6)",
            "-A7"
          ],
          "conclusion": "-A6",
          "natural": "CompoundX was not withdrawn from the market."
        },
        {
          "step_number": 2,
          "rule_applied": "DS",
          "premises_used": [
            "(A6 | -A5)",
            "-A6"
          ],
          "conclusion": "-A5",
          "natural": "CompoundX did not receive a regulatory rejection."
        },
        {
          "step_number": 3,
          "rule_applied": "MT",
          "premises_used": [
            "(-(A4 -> (A1 -> G)) -> A5)",
            "-A5"
          ],
          "conclusion": "(A4 -> (A1 -> G))",
          "natural": "Provided that CompoundX had a successful clinical trial, then its approval implies it is on the market."
        },
        {
          "step_number": 4,
          "rule_applied": "HS",
          "premises_used": [
            "(A3 -> A4)",
            "(A4 -> (A1 -> G))"
          ],
          "conclusion": "(A3 -> (A1 -> G))",
          "natural": "Provided that CompoundX is patented, then its status as an approved compound implies it is on the market."
        },
        {
          "step_number": 5,
          "rule_applied": "HS",
          "premises_used": [
            "(A2 -> A3)",
            "(A3 -> (A1 -> G))"
          ],
          "conclusion": "(A2 -> (A1 -> G))",
          "natural": "Provided that CompoundX was developed by LabAlpha, then the fact that it is an approved compound implies it is on the market."
        },
        {
          "step_number": 6,
          "rule_applied": "MP",
          "premises_used": [
            "(A2 -> (A1 -> G))",
            "A2"
          ],
          "conclusion": "(A1 -> G)",
          "natural": "Provided that CompoundX is an approved compound, it follows that CompoundX is on the market."
        },
        {
          "step_number": 7,
          "rule_applied": "MP",
          "premises_used": [
            "(A1 -> G)",
            "A1"
          ],
          "conclusion": "G",
          "natural": "CompoundX is on the market."
        }
      ]
    },
    {
      "id": 2,
      "family_id": 2,
      "path_type": "core",
      "branch_from": null,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "MP",
          "premises_used": [
            "(A15 -> -A14)",
            "A15"
          ],
          "conclusion": "-A14",
          "natural": "It is not the case that a product recall occurred for CompoundX."
        },
        {
          "step_number": 2,
          "rule_applied": "MT",
          "premises_used": [
            "(-(A11 -> A13) -> A14)",
            "-A14"
          ],
          "conclusion": "(A11 -> A13)",
          "natural": "Whenever a safety issue for CompoundX was reported, the FDA is investigating CompoundX."
        },
        {
          "step_number": 3,
          "rule_applied": "HS",
          "premises_used": [
            "(A11 -> A13)",
            "(A13 -> (A10 -> A9))"
          ],
          "conclusion": "(A11 -> (A10 -> A9))",
          "natural": "If a safety issue for CompoundX was reported, then, whenever a generic version is available, the patent for CompoundX has expired."
        },
        {
          "step_number": 4,
          "rule_applied": "DE",
          "premises_used": [
            "(A11 | A12)",
            "(A11 -> (A10 -> A9))",
            "(A12 -> (A10 -> A9))"
          ],
          "conclusion": "(A10 -> A9)",
          "natural": "Under the condition that a generic version of CompoundX is available, the patent for CompoundX has expired."
        },
        {
          "step_number": 5,
          "rule_applied": "HS",
          "premises_used": [
            "(-A8 -> A10)",
            "(A10 -> A9)"
          ],
          "conclusion": "(-A8 -> A9)",
          "natural": "Under the condition that a manufacturing license was not granted for CompoundX, the patent for CompoundX has expired."
        },
        {
          "step_number": 6,
          "rule_applied": "MT",
          "premises_used": [
            "(-A8 -> A9)",
            "-A9"
          ],
          "conclusion": "A8",
          "natural": "A manufacturing license was granted for CompoundX."
        },
        {
          "step_number": 7,
          "rule_applied": "MP",
          "premises_used": [
            "(A8 -> G)",
            "A8"
          ],
          "conclusion": "G",
          "natural": "CompoundX is on the market."
        }
      ]
    },
    {
      "id": 3,
      "family_id": 3,
      "path_type": "core",
      "branch_from": null,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "HS",
          "premises_used": [
            "(A18 -> A19)",
            "(A19 -> A17)"
          ],
          "conclusion": "(A18 -> A17)",
          "natural": "Provided that CompoundX has an extended release mechanism, it follows that CompoundX has improved bioavailability."
        },
        {
          "step_number": 2,
          "rule_applied": "HS",
          "premises_used": [
            "(A16 -> A18)",
            "(A18 -> A17)"
          ],
          "conclusion": "(A16 -> A17)",
          "natural": "Under the condition that a new formulation of CompoundX exists, CompoundX has improved bioavailability."
        },
        {
          "step_number": 3,
          "rule_applied": "HS",
          "premises_used": [
            "(A16 -> A17)",
            "(A17 -> G)"
          ],
          "conclusion": "(A16 -> G)",
          "natural": "Whenever a new formulation of CompoundX exists, CompoundX is on the market."
        },
        {
          "step_number": 4,
          "rule_applied": "MP",
          "premises_used": [
            "(A16 -> G)",
            "A16"
          ],
          "conclusion": "G",
          "natural": "CompoundX is on the market."
        }
      ]
    },
    {
      "id": 4,
      "family_id": 4,
      "path_type": "core",
      "branch_from": null,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "MT",
          "premises_used": [
            "(-(A24 -> A21) -> A25)",
            "-A25"
          ],
          "conclusion": "(A24 -> A21)",
          "natural": "Under the condition that a quality control system is in place for CompoundX, CompoundX is compliant with Good Manufacturing Practices (GMP)."
        },
        {
          "step_number": 2,
          "rule_applied": "HS",
          "premises_used": [
            "(A23 -> A24)",
            "(A24 -> A21)"
          ],
          "conclusion": "(A23 -> A21)",
          "natural": "Provided that process automation was implemented for CompoundX, CompoundX is compliant with Good Manufacturing Practices (GMP)."
        },
        {
          "step_number": 3,
          "rule_applied": "CD",
          "premises_used": [
            "(A22 -> A20)",
            "(A23 -> A21)",
            "(A22 | A23)"
          ],
          "conclusion": "(A20 | A21)",
          "natural": "Either a manufacturing upgrade was performed for CompoundX, or CompoundX is compliant with Good Manufacturing Practices (GMP)."
        },
        {
          "step_number": 4,
          "rule_applied": "DE",
          "premises_used": [
            "(A20 | A21)",
            "(A20 -> G)",
            "(A21 -> G)"
          ],
          "conclusion": "G",
          "natural": "CompoundX is on the market."
        }
      ]
    },
    {
      "id": 5,
      "family_id": 5,
      "path_type": "core",
      "branch_from": null,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "DS",
          "premises_used": [
            "(A30 | (A29 | (A28 -> (-G -> A26))))",
            "-A30"
          ],
          "conclusion": "(A29 | (A28 -> (-G -> A26)))",
          "natural": "Either an alternative supplier was found for CompoundX, or a raw material shortage implies that the absence of CompoundX from the market leads to a production delay."
        },
        {
          "step_number": 2,
          "rule_applied": "DS",
          "premises_used": [
            "(A29 | (A28 -> (-G -> A26)))",
            "-A29"
          ],
          "conclusion": "(A28 -> (-G -> A26))",
          "natural": "If a raw material shortage affected CompoundX, then, given that CompoundX is not on the market, production of CompoundX was delayed."
        },
        {
          "step_number": 3,
          "rule_applied": "HS",
          "premises_used": [
            "(A27 -> A28)",
            "(A28 -> (-G -> A26))"
          ],
          "conclusion": "(A27 -> (-G -> A26))",
          "natural": "Should a supply chain disruption affect CompoundX, then, if CompoundX is not on the market, production of CompoundX was delayed."
        },
        {
          "step_number": 4,
          "rule_applied": "MP",
          "premises_used": [
            "(A27 -> (-G -> A26))",
            "A27"
          ],
          "conclusion": "(-G -> A26)",
          "natural": "Should CompoundX not be on the market, then production of CompoundX was delayed."
        },
        {
          "step_number": 5,
          "rule_applied": "RAA",
          "premises_used": [
            "(-G -> A26)",
            "(-G -> -A26)"
          ],
          "conclusion": "G",
          "natural": "CompoundX is on the market."
        }
      ]
    },
    {
      "id": 6,
      "family_id": 4,
      "path_type": "branch",
      "branch_from": 1,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "RAA",
          "premises_used": [
            "(-(A34 -> A36) -> A37)",
            "(-(A34 -> A36) -> -A37)"
          ],
          "conclusion": "(A34 -> A36)",
          "natural": "If a system integration failure occurred for CompoundX, then a validation error occurred for CompoundX."
        },
        {
          "step_number": 2,
          "rule_applied": "HS",
          "premises_used": [
            "(A34 -> A36)",
            "(A36 -> -A35)"
          ],
          "conclusion": "(A34 -> -A35)",
          "natural": "Provided that a system integration failure occurred for CompoundX, it is not the case that data corruption occurred for CompoundX."
        },
        {
          "step_number": 3,
          "rule_applied": "RAA",
          "premises_used": [
            "(A34 -> A35)",
            "(A34 -> -A35)"
          ],
          "conclusion": "-A34",
          "natural": "A system integration failure did not occur for CompoundX."
        },
        {
          "step_number": 4,
          "rule_applied": "MT",
          "premises_used": [
            "(-(A32 | A33) -> A34)",
            "-A34"
          ],
          "conclusion": "(A32 | A33)",
          "natural": "Either software was implemented for CompoundX, or hardware was installed for CompoundX."
        },
        {
          "step_number": 5,
          "rule_applied": "DE",
          "premises_used": [
            "(A32 | A33)",
            "(A32 -> (A23 -> A31))",
            "(A33 -> (A23 -> A31))"
          ],
          "conclusion": "(A23 -> A31)",
          "natural": "Whenever process automation was implemented for CompoundX, a batch tracking system is in place for CompoundX."
        },
        {
          "step_number": 6,
          "rule_applied": "HS",
          "premises_used": [
            "(A23 -> A31)",
            "(A31 -> A21)"
          ],
          "conclusion": "(A23 -> A21)",
          "natural": "Provided that process automation was implemented for CompoundX, CompoundX is compliant with Good Manufacturing Practices (GMP)."
        },
        {
          "step_number": 7,
          "rule_applied": "CD",
          "premises_used": [
            "(A22 -> A20)",
            "(A23 -> A21)",
            "(A22 | A23)"
          ],
          "conclusion": "(A20 | A21)",
          "natural": "Either a manufacturing upgrade was performed for CompoundX, or CompoundX is compliant with Good Manufacturing Practices (GMP)."
        },
        {
          "step_number": 8,
          "rule_applied": "DE",
          "premises_used": [
            "(A20 | A21)",
            "(A20 -> G)",
            "(A21 -> G)"
          ],
          "conclusion": "G",
          "natural": "CompoundX is on the market."
        }
      ]
    },
    {
      "id": 7,
      "family_id": 5,
      "path_type": "branch",
      "branch_from": 2,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "RAA",
          "premises_used": [
            "(-(A46 | -A45) -> A47)",
            "(-(A46 | -A45) -> -A47)"
          ],
          "conclusion": "(A46 | -A45)",
          "natural": "Either regulatory approval was received for CompoundX, or authorization was not denied for CompoundX."
        },
        {
          "step_number": 2,
          "rule_applied": "DS",
          "premises_used": [
            "(A46 | -A45)",
            "-A46"
          ],
          "conclusion": "-A45",
          "natural": "Authorization was not denied for CompoundX."
        },
        {
          "step_number": 3,
          "rule_applied": "MT",
          "premises_used": [
            "(-(A43 -> A44) -> A45)",
            "-A45"
          ],
          "conclusion": "(A43 -> A44)",
          "natural": "Whenever management approval was obtained for CompoundX, board authorization was obtained for CompoundX."
        },
        {
          "step_number": 4,
          "rule_applied": "HS",
          "premises_used": [
            "(A43 -> A44)",
            "(A44 -> A39)"
          ],
          "conclusion": "(A43 -> A39)",
          "natural": "If management approval was obtained for CompoundX, then a contingency plan was activated for CompoundX."
        },
        {
          "step_number": 5,
          "rule_applied": "HS",
          "premises_used": [
            "(A41 -> A43)",
            "(A43 -> A39)"
          ],
          "conclusion": "(A41 -> A39)",
          "natural": "Under the condition that a crisis management team was formed for CompoundX, a contingency plan was activated for CompoundX."
        },
        {
          "step_number": 6,
          "rule_applied": "CD",
          "premises_used": [
            "(A41 -> A39)",
            "(A42 -> A40)",
            "(A41 | A42)"
          ],
          "conclusion": "(A39 | A40)",
          "natural": "Either a contingency plan was activated for CompoundX, or an emergency protocol was executed for CompoundX."
        },
        {
          "step_number": 7,
          "rule_applied": "DE",
          "premises_used": [
            "(A39 | A40)",
            "(A39 -> (A38 | (A27 -> (-G -> A26))))",
            "(A40 -> (A38 | (A27 -> (-G -> A26))))"
          ],
          "conclusion": "(A38 | (A27 -> (-G -> A26)))",
          "natural": "Either a backup supplier is available for CompoundX, or a supply chain disruption implies a production delay when the product is not on the market."
        },
        {
          "step_number": 8,
          "rule_applied": "DS",
          "premises_used": [
            "(A38 | (A27 -> (-G -> A26)))",
            "-A38"
          ],
          "conclusion": "(A27 -> (-G -> A26))",
          "natural": "Should a supply chain disruption affect CompoundX, then, if CompoundX is not on the market, production of CompoundX was delayed."
        },
        {
          "step_number": 9,
          "rule_applied": "MP",
          "premises_used": [
            "(A27 -> (-G -> A26))",
            "A27"
          ],
          "conclusion": "(-G -> A26)",
          "natural": "Should CompoundX not be on the market, then production of CompoundX was delayed."
        },
        {
          "step_number": 10,
          "rule_applied": "RAA",
          "premises_used": [
            "(-G -> A26)",
            "(-G -> -A26)"
          ],
          "conclusion": "G",
          "natural": "CompoundX is on the market."
        }
      ]
    },
    {
      "id": 8,
      "family_id": 5,
      "path_type": "branch",
      "branch_from": 3,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "HS",
          "premises_used": [
            "(-G -> A49)",
            "(A49 -> A48)"
          ],
          "conclusion": "(-G -> A48)",
          "natural": "If CompoundX is not on the market, then production of CompoundX was rescheduled."
        },
        {
          "step_number": 2,
          "rule_applied": "HS",
          "premises_used": [
            "(-G -> A48)",
            "(A48 -> A26)"
          ],
          "conclusion": "(-G -> A26)",
          "natural": "Should CompoundX not be on the market, then production of CompoundX was delayed."
        },
        {
          "step_number": 3,
          "rule_applied": "RAA",
          "premises_used": [
            "(-G -> A26)",
            "(-G -> -A26)"
          ],
          "conclusion": "G",
          "natural": "CompoundX is on the market."
        }
      ]
    },
    {
      "id": 9,
      "family_id": 5,
      "path_type": "branch",
      "branch_from": 2,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "RAA",
          "premises_used": [
            "(-(A53 -> (A27 -> (-G -> A26))) -> A54)",
            "(-(A53 -> (A27 -> (-G -> A26))) -> -A54)"
          ],
          "conclusion": "(A53 -> (A27 -> (-G -> A26)))",
          "natural": "Should supervisor approval be obtained for CompoundX, then a supply chain disruption leads to a production delay if the product is not on the market."
        },
        {
          "step_number": 2,
          "rule_applied": "HS",
          "premises_used": [
            "(A52 -> A53)",
            "(A53 -> (A27 -> (-G -> A26)))"
          ],
          "conclusion": "(A52 -> (A27 -> (-G -> A26)))",
          "natural": "Under the condition that a manual override was authorized for CompoundX, a supply chain disruption implies a production delay when the product is not on the market."
        },
        {
          "step_number": 3,
          "rule_applied": "CD",
          "premises_used": [
            "(A51 -> A50)",
            "(A52 -> (A27 -> (-G -> A26)))",
            "(A51 | A52)"
          ],
          "conclusion": "(A50 | (A27 -> (-G -> A26)))",
          "natural": "Either an alternative process is available for CompoundX, or a supply chain disruption implies a production delay when the product is not on the market."
        },
        {
          "step_number": 4,
          "rule_applied": "DS",
          "premises_used": [
            "(A50 | (A27 -> (-G -> A26)))",
            "-A50"
          ],
          "conclusion": "(A27 -> (-G -> A26))",
          "natural": "Should a supply chain disruption affect CompoundX, then, if CompoundX is not on the market, production of CompoundX was delayed."
        },
        {
          "step_number": 5,
          "rule_applied": "MP",
          "premises_used": [
            "(A27 -> (-G -> A26))",
            "A27"
          ],
          "conclusion": "(-G -> A26)",
          "natural": "Should CompoundX not be on the market, then production of CompoundX was delayed."
        },
        {
          "step_number": 6,
          "rule_applied": "RAA",
          "premises_used": [
            "(-G -> A26)",
            "(-G -> -A26)"
          ],
          "conclusion": "G",
          "natural": "CompoundX is on the market."
        }
      ]
    }
  ],
  "translations": {
    "domain_theme": "Pharmaceutical Manufacturing",
    "atomic_facts": {
      "A1": "approved_compound(CompoundX)",
      "A2": "developed_by(CompoundX, LabAlpha)",
      "A3": "patented(CompoundX)",
      "A4": "clinical_trial_success(CompoundX)",
      "A5": "regulatory_rejection(CompoundX)",
      "A6": "market_withdrawal(CompoundX)",
      "A7": "production_halt(CompoundX)",
      "A8": "manufacturing_license_granted(CompoundX)",
      "A9": "patent_expired(CompoundX)",
      "A10": "generic_available(CompoundX)",
      "A11": "safety_issue_reported(CompoundX)",
      "A12": "adverse_event_study(CompoundX)",
      "A13": "fda_investigation(CompoundX)",
      "A14": "product_recall(CompoundX)",
      "A15": "recall_order_issued(CompoundX)",
      "A16": "new_formulation(CompoundX)",
      "A17": "improved_bioavailability(CompoundX)",
      "A18": "extended_release(CompoundX)",
      "A19": "reduced_dosing(CompoundX)",
      "A20": "manufacturing_upgrade(CompoundX)",
      "A21": "gmp_compliance(CompoundX)",
      "A22": "equipment_modernization(CompoundX)",
      "A23": "process_automation(CompoundX)",
      "A24": "quality_control_system(CompoundX)",
      "A25": "compliance_failure(CompoundX)",
      "A26": "production_delay(CompoundX)",
      "A27": "supply_chain_disruption(CompoundX)",
      "A28": "raw_material_shortage(CompoundX)",
      "A29": "alternative_supplier_found(CompoundX)",
      "A30": "import_license_secured(CompoundX)",
      "A31": "batch_tracking_system(CompoundX)",
      "A32": "software_implementation(CompoundX)",
      "A33": "hardware_installation(CompoundX)",
      "A34": "system_integration_failure(CompoundX)",
      "A35": "data_corruption(CompoundX)",
      "A36": "validation_error(CompoundX)",
      "A37": "validation_success(CompoundX)",
      "A38": "backup_supplier_available(CompoundX)",
      "A39": "contingency_plan_activated(CompoundX)",
      "A40": "emergency_protocol_executed(CompoundX)",
      "A41": "crisis_management_team(CompoundX)",
      "A42": "emergency_response_unit(CompoundX)",
      "A43": "management_approval(CompoundX)",
      "A44": "board_authorization(CompoundX)",
      "A45": "authorization_denied(CompoundX)",
      "A46": "regulatory_approval_received(CompoundX)",
      "A47": "approval_pending(CompoundX)",
      "A48": "production_rescheduled(CompoundX)",
      "A49": "timeline_adjusted(CompoundX)",
      "A50": "alternative_process_available(CompoundX)",
      "A51": "process_validation_complete(CompoundX)",
      "A52": "manual_override_authorized(CompoundX)",
      "A53": "supervisor_approval(CompoundX)",
      "A54": "override_rejected(CompoundX)",
      "G": "product_on_market(CompoundX)"
    },
    "natural_facts": {
      "A1": "CompoundX is an approved compound.",
      "A2": "CompoundX was developed by LabAlpha.",
      "A3": "CompoundX is patented.",
      "A4": "CompoundX had a successful clinical trial.",
      "A5": "CompoundX received a regulatory rejection.",
      "A6": "CompoundX was withdrawn from the market.",
      "A7": "CompoundX production was halted.",
      "A8": "A manufacturing license was granted for CompoundX.",
      "A9": "The patent for CompoundX has expired.",
      "A10": "A generic version of CompoundX is available.",
      "A11": "A safety issue for CompoundX was reported.",
      "A12": "An adverse event study was conducted on CompoundX.",
      "A13": "The FDA is investigating CompoundX.",
      "A14": "A product recall occurred for CompoundX.",
      "A15": "A recall order was issued for CompoundX.",
      "A16": "A new formulation of CompoundX exists.",
      "A17": "CompoundX has improved bioavailability.",
      "A18": "CompoundX has an extended release mechanism.",
      "A19": "CompoundX dosing has been reduced.",
      "A20": "A manufacturing upgrade was performed for CompoundX.",
      "A21": "CompoundX is compliant with Good Manufacturing Practices (GMP).",
      "A22": "Equipment modernization was undertaken for CompoundX.",
      "A23": "Process automation was implemented for CompoundX.",
      "A24": "A quality control system is in place for CompoundX.",
      "A25": "A compliance failure occurred for CompoundX.",
      "A26": "Production of CompoundX was delayed.",
      "A27": "A supply chain disruption affected CompoundX.",
      "A28": "A raw material shortage affected CompoundX.",
      "A29": "An alternative supplier was found for CompoundX.",
      "A30": "An import license was secured for CompoundX.",
      "A31": "A batch tracking system is in place for CompoundX.",
      "A32": "Software was implemented for CompoundX.",
      "A33": "Hardware was installed for CompoundX.",
      "A34": "A system integration failure occurred for CompoundX.",
      "A35": "Data corruption occurred for CompoundX.",
      "A36": "A validation error occurred for CompoundX.",
      "A37": "Validation was successful for CompoundX.",
      "A38": "A backup supplier is available for CompoundX.",
      "A39": "A contingency plan was activated for CompoundX.",
      "A40": "An emergency protocol was executed for CompoundX.",
      "A41": "A crisis management team was formed for CompoundX.",
      "A42": "An emergency response unit was deployed for CompoundX.",
      "A43": "Management approval was obtained for CompoundX.",
      "A44": "Board authorization was obtained for CompoundX.",
      "A45": "Authorization was denied for CompoundX.",
      "A46": "Regulatory approval was received for CompoundX.",
      "A47": "Approval is pending for CompoundX.",
      "A48": "Production of CompoundX was rescheduled.",
      "A49": "The timeline for CompoundX was adjusted.",
      "A50": "An alternative process is available for CompoundX.",
      "A51": "Process validation is complete for CompoundX.",
      "A52": "A manual override was authorized for CompoundX.",
      "A53": "Supervisor approval was obtained for CompoundX.",
      "A54": "An override was rejected for CompoundX.",
      "G": "CompoundX is on the market."
    },
    "prover9_expressions": [
      "(approved_compound(CompoundX) -> product_on_market(CompoundX))",
      "(generic_available(CompoundX) -> patent_expired(CompoundX))",
      "(safety_issue_reported(CompoundX) -> (generic_available(CompoundX) -> patent_expired(CompoundX)))",
      "(safety_issue_reported(CompoundX) -> fda_investigation(CompoundX))",
      "(safety_issue_reported(CompoundX) | adverse_event_study(CompoundX))",
      "(adverse_event_study(CompoundX) -> (generic_available(CompoundX) -> patent_expired(CompoundX)))",
      "(fda_investigation(CompoundX) -> (generic_available(CompoundX) -> patent_expired(CompoundX)))",
      "(recall_order_issued(CompoundX) -> -product_recall(CompoundX))",
      "(new_formulation(CompoundX) -> improved_bioavailability(CompoundX))",
      "(new_formulation(CompoundX) -> extended_release(CompoundX))",
      "(new_formulation(CompoundX) -> product_on_market(CompoundX))",
      "(improved_bioavailability(CompoundX) -> product_on_market(CompoundX))",
      "(extended_release(CompoundX) -> improved_bioavailability(CompoundX))",
      "(extended_release(CompoundX) -> reduced_dosing(CompoundX))",
      "(reduced_dosing(CompoundX) -> improved_bioavailability(CompoundX))",
      "(developed_by(CompoundX, LabAlpha) -> (approved_compound(CompoundX) -> product_on_market(CompoundX)))",
      "(developed_by(CompoundX, LabAlpha) -> patented(CompoundX))",
      "(manufacturing_upgrade(CompoundX) -> product_on_market(CompoundX))",
      "(manufacturing_upgrade(CompoundX) | gmp_compliance(CompoundX))",
      "(gmp_compliance(CompoundX) -> product_on_market(CompoundX))",
      "(equipment_modernization(CompoundX) -> manufacturing_upgrade(CompoundX))",
      "(equipment_modernization(CompoundX) | process_automation(CompoundX))",
      "(process_automation(CompoundX) -> gmp_compliance(CompoundX))",
      "(process_automation(CompoundX) -> quality_control_system(CompoundX))",
      "(process_automation(CompoundX) -> batch_tracking_system(CompoundX))",
      "(quality_control_system(CompoundX) -> gmp_compliance(CompoundX))",
      "(supply_chain_disruption(CompoundX) -> (-product_on_market(CompoundX) -> production_delay(CompoundX)))",
      "(supply_chain_disruption(CompoundX) -> raw_material_shortage(CompoundX))",
      "(raw_material_shortage(CompoundX) -> (-product_on_market(CompoundX) -> production_delay(CompoundX)))",
      "(alternative_supplier_found(CompoundX) | (raw_material_shortage(CompoundX) -> (-product_on_market(CompoundX) -> production_delay(CompoundX))))",
      "(patented(CompoundX) -> (approved_compound(CompoundX) -> product_on_market(CompoundX)))",
      "(patented(CompoundX) -> clinical_trial_success(CompoundX))",
      "(import_license_secured(CompoundX) | (alternative_supplier_found(CompoundX) | (raw_material_shortage(CompoundX) -> (-product_on_market(CompoundX) -> production_delay(CompoundX)))))",
      "(batch_tracking_system(CompoundX) -> gmp_compliance(CompoundX))",
      "(software_implementation(CompoundX) -> (process_automation(CompoundX) -> batch_tracking_system(CompoundX)))",
      "(software_implementation(CompoundX) | hardware_installation(CompoundX))",
      "(hardware_installation(CompoundX) -> (process_automation(CompoundX) -> batch_tracking_system(CompoundX)))",
      "(system_integration_failure(CompoundX) -> data_corruption(CompoundX))",
      "(system_integration_failure(CompoundX) -> validation_error(CompoundX))",
      "(system_integration_failure(CompoundX) -> -data_corruption(CompoundX))",
      "(validation_error(CompoundX) -> -data_corruption(CompoundX))",
      "(backup_supplier_available(CompoundX) | (supply_chain_disruption(CompoundX) -> (-product_on_market(CompoundX) -> production_delay(CompoundX))))",
      "(contingency_plan_activated(CompoundX) -> (backup_supplier_available(CompoundX) | (supply_chain_disruption(CompoundX) -> (-product_on_market(CompoundX) -> production_delay(CompoundX)))))",
      "(contingency_plan_activated(CompoundX) | emergency_protocol_executed(CompoundX))",
      "(clinical_trial_success(CompoundX) -> (approved_compound(CompoundX) -> product_on_market(CompoundX)))",
      "(emergency_protocol_executed(CompoundX) -> (backup_supplier_available(CompoundX) | (supply_chain_disruption(CompoundX) -> (-product_on_market(CompoundX) -> production_delay(CompoundX)))))",
      "(crisis_management_team(CompoundX) -> contingency_plan_activated(CompoundX))",
      "(crisis_management_team(CompoundX) -> management_approval(CompoundX))",
      "(crisis_management_team(CompoundX) | emergency_response_unit(CompoundX))",
      "(emergency_response_unit(CompoundX) -> emergency_protocol_executed(CompoundX))",
      "(management_approval(CompoundX) -> contingency_plan_activated(CompoundX))",
      "(management_approval(CompoundX) -> board_authorization(CompoundX))",
      "(board_authorization(CompoundX) -> contingency_plan_activated(CompoundX))",
      "(regulatory_approval_received(CompoundX) | -authorization_denied(CompoundX))",
      "(production_rescheduled(CompoundX) -> production_delay(CompoundX))",
      "(timeline_adjusted(CompoundX) -> production_rescheduled(CompoundX))",
      "(alternative_process_available(CompoundX) | (supply_chain_disruption(CompoundX) -> (-product_on_market(CompoundX) -> production_delay(CompoundX))))",
      "(process_validation_complete(CompoundX) -> alternative_process_available(CompoundX))",
      "(process_validation_complete(CompoundX) | manual_override_authorized(CompoundX))",
      "(manual_override_authorized(CompoundX) -> (supply_chain_disruption(CompoundX) -> (-product_on_market(CompoundX) -> production_delay(CompoundX))))",
      "(manual_override_authorized(CompoundX) -> supervisor_approval(CompoundX))",
      "(supervisor_approval(CompoundX) -> (supply_chain_disruption(CompoundX) -> (-product_on_market(CompoundX) -> production_delay(CompoundX))))",
      "(market_withdrawal(CompoundX) | -regulatory_rejection(CompoundX))",
      "(production_halt(CompoundX) | -market_withdrawal(CompoundX))",
      "(manufacturing_license_granted(CompoundX) -> product_on_market(CompoundX))",
      "(-(safety_issue_reported(CompoundX) -> fda_investigation(CompoundX)) -> product_recall(CompoundX))",
      "(-(quality_control_system(CompoundX) -> gmp_compliance(CompoundX)) -> compliance_failure(CompoundX))",
      "(-(software_implementation(CompoundX) | hardware_installation(CompoundX)) -> system_integration_failure(CompoundX))",
      "(-(system_integration_failure(CompoundX) -> validation_error(CompoundX)) -> validation_success(CompoundX))",
      "(-(system_integration_failure(CompoundX) -> validation_error(CompoundX)) -> -validation_success(CompoundX))",
      "(-(clinical_trial_success(CompoundX) -> (approved_compound(CompoundX) -> product_on_market(CompoundX))) -> regulatory_rejection(CompoundX))",
      "(-(management_approval(CompoundX) -> board_authorization(CompoundX)) -> authorization_denied(CompoundX))",
      "(-(regulatory_approval_received(CompoundX) | -authorization_denied(CompoundX)) -> approval_pending(CompoundX))",
      "(-(regulatory_approval_received(CompoundX) | -authorization_denied(CompoundX)) -> -approval_pending(CompoundX))",
      "(-(supervisor_approval(CompoundX) -> (supply_chain_disruption(CompoundX) -> (-product_on_market(CompoundX) -> production_delay(CompoundX)))) -> override_rejected(CompoundX))",
      "(-(supervisor_approval(CompoundX) -> (supply_chain_disruption(CompoundX) -> (-product_on_market(CompoundX) -> production_delay(CompoundX)))) -> -override_rejected(CompoundX))",
      "(-manufacturing_license_granted(CompoundX) -> generic_available(CompoundX))",
      "(-manufacturing_license_granted(CompoundX) -> patent_expired(CompoundX))",
      "(-product_on_market(CompoundX) -> production_delay(CompoundX))",
      "(-product_on_market(CompoundX) -> production_rescheduled(CompoundX))",
      "(-product_on_market(CompoundX) -> timeline_adjusted(CompoundX))",
      "(-product_on_market(CompoundX) -> -production_delay(CompoundX))",
      "approved_compound(CompoundX)",
      "recall_order_issued(CompoundX)",
      "new_formulation(CompoundX)",
      "developed_by(CompoundX, LabAlpha)",
      "supply_chain_disruption(CompoundX)",
      "manufacturing_license_granted(CompoundX)",
      "product_on_market(CompoundX)",
      "-product_recall(CompoundX)",
      "-compliance_failure(CompoundX)",
      "-alternative_supplier_found(CompoundX)",
      "-import_license_secured(CompoundX)",
      "-system_integration_failure(CompoundX)",
      "-backup_supplier_available(CompoundX)",
      "-authorization_denied(CompoundX)",
      "-regulatory_approval_received(CompoundX)",
      "-regulatory_rejection(CompoundX)",
      "-alternative_process_available(CompoundX)",
      "-market_withdrawal(CompoundX)",
      "-production_halt(CompoundX)",
      "-patent_expired(CompoundX)"
    ],
    "natural_expressions": [
      "Provided that CompoundX is an approved compound, it follows that CompoundX is on the market.",
      "Under the condition that a generic version of CompoundX is available, the patent for CompoundX has expired.",
      "If a safety issue for CompoundX was reported, then, whenever a generic version is available, the patent for CompoundX has expired.",
      "Whenever a safety issue for CompoundX was reported, the FDA is investigating CompoundX.",
      "Either a safety issue for CompoundX was reported, or an adverse event study was conducted on CompoundX.",
      "Should an adverse event study have been conducted on CompoundX, then it is the case that the availability of a generic version implies the patent for CompoundX has expired.",
      "If the FDA is investigating CompoundX, then the availability of a generic version necessitates that the patent for CompoundX has expired.",
      "Provided that a recall order was issued for CompoundX, it is not the case that a product recall occurred for CompoundX.",
      "Under the condition that a new formulation of CompoundX exists, CompoundX has improved bioavailability.",
      "If a new formulation of CompoundX exists, then CompoundX has an extended release mechanism.",
      "Whenever a new formulation of CompoundX exists, CompoundX is on the market.",
      "Should CompoundX have improved bioavailability, then CompoundX is on the market.",
      "Provided that CompoundX has an extended release mechanism, it follows that CompoundX has improved bioavailability.",
      "If CompoundX has an extended release mechanism, then CompoundX dosing has been reduced.",
      "Under the condition that CompoundX dosing has been reduced, CompoundX has improved bioavailability.",
      "Provided that CompoundX was developed by LabAlpha, then the fact that it is an approved compound implies it is on the market.",
      "If CompoundX was developed by LabAlpha, then CompoundX is patented.",
      "Whenever a manufacturing upgrade was performed for CompoundX, CompoundX is on the market.",
      "Either a manufacturing upgrade was performed for CompoundX, or CompoundX is compliant with Good Manufacturing Practices (GMP).",
      "Should CompoundX be compliant with Good Manufacturing Practices (GMP), then CompoundX is on the market.",
      "Under the condition that equipment modernization was undertaken for CompoundX, a manufacturing upgrade was performed for CompoundX.",
      "Either equipment modernization was undertaken for CompoundX, or process automation was implemented for CompoundX.",
      "Provided that process automation was implemented for CompoundX, CompoundX is compliant with Good Manufacturing Practices (GMP).",
      "If process automation was implemented for CompoundX, then a quality control system is in place for CompoundX.",
      "Whenever process automation was implemented for CompoundX, a batch tracking system is in place for CompoundX.",
      "Under the condition that a quality control system is in place for CompoundX, CompoundX is compliant with Good Manufacturing Practices (GMP).",
      "Should a supply chain disruption affect CompoundX, then, if CompoundX is not on the market, production of CompoundX was delayed.",
      "Provided that a supply chain disruption affected CompoundX, a raw material shortage affected CompoundX.",
      "If a raw material shortage affected CompoundX, then, given that CompoundX is not on the market, production of CompoundX was delayed.",
      "Either an alternative supplier was found for CompoundX, or a raw material shortage implies that the absence of CompoundX from the market leads to a production delay.",
      "Provided that CompoundX is patented, then its status as an approved compound implies it is on the market.",
      "If CompoundX is patented, then CompoundX had a successful clinical trial.",
      "Either an import license was secured for CompoundX, or an alternative supplier was found, or a raw material shortage leads to a production delay when the product is not on the market.",
      "Under the condition that a batch tracking system is in place for CompoundX, CompoundX is compliant with Good Manufacturing Practices (GMP).",
      "Provided that software was implemented for CompoundX, then the implementation of process automation necessitates that a batch tracking system is in place.",
      "Either software was implemented for CompoundX, or hardware was installed for CompoundX.",
      "Should hardware be installed for CompoundX, then the implementation of process automation implies a batch tracking system is in place.",
      "Whenever a system integration failure occurred for CompoundX, data corruption occurred for CompoundX.",
      "If a system integration failure occurred for CompoundX, then a validation error occurred for CompoundX.",
      "Provided that a system integration failure occurred for CompoundX, it is not the case that data corruption occurred for CompoundX.",
      "Under the condition that a validation error occurred for CompoundX, data corruption did not occur for CompoundX.",
      "Either a backup supplier is available for CompoundX, or a supply chain disruption implies a production delay when the product is not on the market.",
      "Should a contingency plan be activated for CompoundX, then either a backup supplier is available, or a supply chain disruption leads to a production delay if the product is not on the market.",
      "Either a contingency plan was activated for CompoundX, or an emergency protocol was executed for CompoundX.",
      "Provided that CompoundX had a successful clinical trial, then its approval implies it is on the market.",
      "If an emergency protocol was executed for CompoundX, then either a backup supplier is available, or a supply chain disruption necessitates a production delay when the product is not on the market.",
      "Under the condition that a crisis management team was formed for CompoundX, a contingency plan was activated for CompoundX.",
      "Should a crisis management team be formed for CompoundX, management approval was obtained for CompoundX.",
      "Either a crisis management team was formed for CompoundX, or an emergency response unit was deployed for CompoundX.",
      "Provided that an emergency response unit was deployed for CompoundX, an emergency protocol was executed for CompoundX.",
      "If management approval was obtained for CompoundX, then a contingency plan was activated for CompoundX.",
      "Whenever management approval was obtained for CompoundX, board authorization was obtained for CompoundX.",
      "Under the condition that board authorization was obtained for CompoundX, a contingency plan was activated for CompoundX.",
      "Either regulatory approval was received for CompoundX, or authorization was not denied for CompoundX.",
      "Should production of CompoundX be rescheduled, then production of CompoundX was delayed.",
      "Provided that the timeline for CompoundX was adjusted, production of CompoundX was rescheduled.",
      "Either an alternative process is available for CompoundX, or a supply chain disruption implies a production delay when the product is not on the market.",
      "If process validation is complete for CompoundX, then an alternative process is available for CompoundX.",
      "Either process validation is complete for CompoundX, or a manual override was authorized for CompoundX.",
      "Under the condition that a manual override was authorized for CompoundX, a supply chain disruption implies a production delay when the product is not on the market.",
      "Provided that a manual override was authorized for CompoundX, supervisor approval was obtained for CompoundX.",
      "Should supervisor approval be obtained for CompoundX, then a supply chain disruption leads to a production delay if the product is not on the market.",
      "Either CompoundX was withdrawn from the market, or it is not the case that CompoundX received a regulatory rejection.",
      "Either production of CompoundX was halted, or CompoundX was not withdrawn from the market.",
      "If a manufacturing license was granted for CompoundX, then CompoundX is on the market.",
      "If it is not the case that a reported safety issue leads to an FDA investigation, then a product recall occurred for CompoundX.",
      "Provided that it is false that a quality control system implies GMP compliance, then a compliance failure occurred for CompoundX.",
      "Under the condition that neither software was implemented nor hardware was installed for CompoundX, a system integration failure occurred for CompoundX.",
      "If it is not the case that a system integration failure leads to a validation error, then validation was successful for CompoundX.",
      "Should it be false that a system integration failure necessitates a validation error, then validation was not successful for CompoundX.",
      "Whenever it is not the case that a successful clinical trial implies approval leads to the product being on the market, then CompoundX received a regulatory rejection.",
      "Provided that it is false that management approval implies board authorization, then authorization was denied for CompoundX.",
      "If it is not the case that either regulatory approval was received or authorization was not denied, then approval is pending for CompoundX.",
      "Under the condition that it is false that regulatory approval was received or authorization was not denied, approval is not pending for CompoundX.",
      "Should it be false that supervisor approval implies a supply chain disruption leads to a production delay when the product is not on the market, then an override was rejected for CompoundX.",
      "Provided that it is not the case that supervisor approval necessitates a supply chain disruption causing a production delay without the product on the market, then an override was not rejected for CompoundX.",
      "If a manufacturing license was not granted for CompoundX, then a generic version of CompoundX is available.",
      "Under the condition that a manufacturing license was not granted for CompoundX, the patent for CompoundX has expired.",
      "Should CompoundX not be on the market, then production of CompoundX was delayed.",
      "If CompoundX is not on the market, then production of CompoundX was rescheduled.",
      "Provided that CompoundX is not on the market, the timeline for CompoundX was adjusted.",
      "Under the condition that CompoundX is not on the market, it is not the case that production of CompoundX was delayed.",
      "CompoundX is an approved compound.",
      "A recall order was issued for CompoundX.",
      "A new formulation of CompoundX exists.",
      "CompoundX was developed by LabAlpha.",
      "A supply chain disruption affected CompoundX.",
      "A manufacturing license was granted for CompoundX.",
      "CompoundX is on the market.",
      "It is not the case that a product recall occurred for CompoundX.",
      "A compliance failure did not occur for CompoundX.",
      "An alternative supplier was not found for CompoundX.",
      "An import license was not secured for CompoundX.",
      "A system integration failure did not occur for CompoundX.",
      "A backup supplier is not available for CompoundX.",
      "Authorization was not denied for CompoundX.",
      "Regulatory approval was not received for CompoundX.",
      "CompoundX did not receive a regulatory rejection.",
      "An alternative process is not available for CompoundX.",
      "CompoundX was not withdrawn from the market.",
      "Production of CompoundX was not halted.",
      "The patent for CompoundX has not expired."
    ],
    "node_mappings": {
      "(A1 → G)": {
        "formal": "(A1 → G)",
        "prover9": "(A1 -> G)",
        "prover9_expression": "(approved_compound(CompoundX) -> product_on_market(CompoundX))",
        "natural": "Provided that CompoundX is an approved compound, it follows that CompoundX is on the market."
      },
      "(A10 → A9)": {
        "formal": "(A10 → A9)",
        "prover9": "(A10 -> A9)",
        "prover9_expression": "(generic_available(CompoundX) -> patent_expired(CompoundX))",
        "natural": "Under the condition that a generic version of CompoundX is available, the patent for CompoundX has expired."
      },
      "(A11 → (A10 → A9))": {
        "formal": "(A11 → (A10 → A9))",
        "prover9": "(A11 -> (A10 -> A9))",
        "prover9_expression": "(safety_issue_reported(CompoundX) -> (generic_available(CompoundX) -> patent_expired(CompoundX)))",
        "natural": "If a safety issue for CompoundX was reported, then, whenever a generic version is available, the patent for CompoundX has expired."
      },
      "(A11 → A13)": {
        "formal": "(A11 → A13)",
        "prover9": "(A11 -> A13)",
        "prover9_expression": "(safety_issue_reported(CompoundX) -> fda_investigation(CompoundX))",
        "natural": "Whenever a safety issue for CompoundX was reported, the FDA is investigating CompoundX."
      },
      "(A11 ∨ A12)": {
        "formal": "(A11 ∨ A12)",
        "prover9": "(A11 | A12)",
        "prover9_expression": "(safety_issue_reported(CompoundX) | adverse_event_study(CompoundX))",
        "natural": "Either a safety issue for CompoundX was reported, or an adverse event study was conducted on CompoundX."
      },
      "(A12 → (A10 → A9))": {
        "formal": "(A12 → (A10 → A9))",
        "prover9": "(A12 -> (A10 -> A9))",
        "prover9_expression": "(adverse_event_study(CompoundX) -> (generic_available(CompoundX) -> patent_expired(CompoundX)))",
        "natural": "Should an adverse event study have been conducted on CompoundX, then it is the case that the availability of a generic version implies the patent for CompoundX has expired."
      },
      "(A13 → (A10 → A9))": {
        "formal": "(A13 → (A10 → A9))",
        "prover9": "(A13 -> (A10 -> A9))",
        "prover9_expression": "(fda_investigation(CompoundX) -> (generic_available(CompoundX) -> patent_expired(CompoundX)))",
        "natural": "If the FDA is investigating CompoundX, then the availability of a generic version necessitates that the patent for CompoundX has expired."
      },
      "(A15 → ¬A14)": {
        "formal": "(A15 → ¬A14)",
        "prover9": "(A15 -> -A14)",
        "prover9_expression": "(recall_order_issued(CompoundX) -> -product_recall(CompoundX))",
        "natural": "Provided that a recall order was issued for CompoundX, it is not the case that a product recall occurred for CompoundX."
      },
      "(A16 → A17)": {
        "formal": "(A16 → A17)",
        "prover9": "(A16 -> A17)",
        "prover9_expression": "(new_formulation(CompoundX) -> improved_bioavailability(CompoundX))",
        "natural": "Under the condition that a new formulation of CompoundX exists, CompoundX has improved bioavailability."
      },
      "(A16 → A18)": {
        "formal": "(A16 → A18)",
        "prover9": "(A16 -> A18)",
        "prover9_expression": "(new_formulation(CompoundX) -> extended_release(CompoundX))",
        "natural": "If a new formulation of CompoundX exists, then CompoundX has an extended release mechanism."
      },
      "(A16 → G)": {
        "formal": "(A16 → G)",
        "prover9": "(A16 -> G)",
        "prover9_expression": "(new_formulation(CompoundX) -> product_on_market(CompoundX))",
        "natural": "Whenever a new formulation of CompoundX exists, CompoundX is on the market."
      },
      "(A17 → G)": {
        "formal": "(A17 → G)",
        "prover9": "(A17 -> G)",
        "prover9_expression": "(improved_bioavailability(CompoundX) -> product_on_market(CompoundX))",
        "natural": "Should CompoundX have improved bioavailability, then CompoundX is on the market."
      },
      "(A18 → A17)": {
        "formal": "(A18 → A17)",
        "prover9": "(A18 -> A17)",
        "prover9_expression": "(extended_release(CompoundX) -> improved_bioavailability(CompoundX))",
        "natural": "Provided that CompoundX has an extended release mechanism, it follows that CompoundX has improved bioavailability."
      },
      "(A18 → A19)": {
        "formal": "(A18 → A19)",
        "prover9": "(A18 -> A19)",
        "prover9_expression": "(extended_release(CompoundX) -> reduced_dosing(CompoundX))",
        "natural": "If CompoundX has an extended release mechanism, then CompoundX dosing has been reduced."
      },
      "(A19 → A17)": {
        "formal": "(A19 → A17)",
        "prover9": "(A19 -> A17)",
        "prover9_expression": "(reduced_dosing(CompoundX) -> improved_bioavailability(CompoundX))",
        "natural": "Under the condition that CompoundX dosing has been reduced, CompoundX has improved bioavailability."
      },
      "(A2 → (A1 → G))": {
        "formal": "(A2 → (A1 → G))",
        "prover9": "(A2 -> (A1 -> G))",
        "prover9_expression": "(developed_by(CompoundX, LabAlpha) -> (approved_compound(CompoundX) -> product_on_market(CompoundX)))",
        "natural": "Provided that CompoundX was developed by LabAlpha, then the fact that it is an approved compound implies it is on the market."
      },
      "(A2 → A3)": {
        "formal": "(A2 → A3)",
        "prover9": "(A2 -> A3)",
        "prover9_expression": "(developed_by(CompoundX, LabAlpha) -> patented(CompoundX))",
        "natural": "If CompoundX was developed by LabAlpha, then CompoundX is patented."
      },
      "(A20 → G)": {
        "formal": "(A20 → G)",
        "prover9": "(A20 -> G)",
        "prover9_expression": "(manufacturing_upgrade(CompoundX) -> product_on_market(CompoundX))",
        "natural": "Whenever a manufacturing upgrade was performed for CompoundX, CompoundX is on the market."
      },
      "(A20 ∨ A21)": {
        "formal": "(A20 ∨ A21)",
        "prover9": "(A20 | A21)",
        "prover9_expression": "(manufacturing_upgrade(CompoundX) | gmp_compliance(CompoundX))",
        "natural": "Either a manufacturing upgrade was performed for CompoundX, or CompoundX is compliant with Good Manufacturing Practices (GMP)."
      },
      "(A21 → G)": {
        "formal": "(A21 → G)",
        "prover9": "(A21 -> G)",
        "prover9_expression": "(gmp_compliance(CompoundX) -> product_on_market(CompoundX))",
        "natural": "Should CompoundX be compliant with Good Manufacturing Practices (GMP), then CompoundX is on the market."
      },
      "(A22 → A20)": {
        "formal": "(A22 → A20)",
        "prover9": "(A22 -> A20)",
        "prover9_expression": "(equipment_modernization(CompoundX) -> manufacturing_upgrade(CompoundX))",
        "natural": "Under the condition that equipment modernization was undertaken for CompoundX, a manufacturing upgrade was performed for CompoundX."
      },
      "(A22 ∨ A23)": {
        "formal": "(A22 ∨ A23)",
        "prover9": "(A22 | A23)",
        "prover9_expression": "(equipment_modernization(CompoundX) | process_automation(CompoundX))",
        "natural": "Either equipment modernization was undertaken for CompoundX, or process automation was implemented for CompoundX."
      },
      "(A23 → A21)": {
        "formal": "(A23 → A21)",
        "prover9": "(A23 -> A21)",
        "prover9_expression": "(process_automation(CompoundX) -> gmp_compliance(CompoundX))",
        "natural": "Provided that process automation was implemented for CompoundX, CompoundX is compliant with Good Manufacturing Practices (GMP)."
      },
      "(A23 → A24)": {
        "formal": "(A23 → A24)",
        "prover9": "(A23 -> A24)",
        "prover9_expression": "(process_automation(CompoundX) -> quality_control_system(CompoundX))",
        "natural": "If process automation was implemented for CompoundX, then a quality control system is in place for CompoundX."
      },
      "(A23 → A31)": {
        "formal": "(A23 → A31)",
        "prover9": "(A23 -> A31)",
        "prover9_expression": "(process_automation(CompoundX) -> batch_tracking_system(CompoundX))",
        "natural": "Whenever process automation was implemented for CompoundX, a batch tracking system is in place for CompoundX."
      },
      "(A24 → A21)": {
        "formal": "(A24 → A21)",
        "prover9": "(A24 -> A21)",
        "prover9_expression": "(quality_control_system(CompoundX) -> gmp_compliance(CompoundX))",
        "natural": "Under the condition that a quality control system is in place for CompoundX, CompoundX is compliant with Good Manufacturing Practices (GMP)."
      },
      "(A27 → (¬G → A26))": {
        "formal": "(A27 → (¬G → A26))",
        "prover9": "(A27 -> (-G -> A26))",
        "prover9_expression": "(supply_chain_disruption(CompoundX) -> (-product_on_market(CompoundX) -> production_delay(CompoundX)))",
        "natural": "Should a supply chain disruption affect CompoundX, then, if CompoundX is not on the market, production of CompoundX was delayed."
      },
      "(A27 → A28)": {
        "formal": "(A27 → A28)",
        "prover9": "(A27 -> A28)",
        "prover9_expression": "(supply_chain_disruption(CompoundX) -> raw_material_shortage(CompoundX))",
        "natural": "Provided that a supply chain disruption affected CompoundX, a raw material shortage affected CompoundX."
      },
      "(A28 → (¬G → A26))": {
        "formal": "(A28 → (¬G → A26))",
        "prover9": "(A28 -> (-G -> A26))",
        "prover9_expression": "(raw_material_shortage(CompoundX) -> (-product_on_market(CompoundX) -> production_delay(CompoundX)))",
        "natural": "If a raw material shortage affected CompoundX, then, given that CompoundX is not on the market, production of CompoundX was delayed."
      },
      "(A29 ∨ (A28 → (¬G → A26)))": {
        "formal": "(A29 ∨ (A28 → (¬G → A26)))",
        "prover9": "(A29 | (A28 -> (-G -> A26)))",
        "prover9_expression": "(alternative_supplier_found(CompoundX) | (raw_material_shortage(CompoundX) -> (-product_on_market(CompoundX) -> production_delay(CompoundX))))",
        "natural": "Either an alternative supplier was found for CompoundX, or a raw material shortage implies that the absence of CompoundX from the market leads to a production delay."
      },
      "(A3 → (A1 → G))": {
        "formal": "(A3 → (A1 → G))",
        "prover9": "(A3 -> (A1 -> G))",
        "prover9_expression": "(patented(CompoundX) -> (approved_compound(CompoundX) -> product_on_market(CompoundX)))",
        "natural": "Provided that CompoundX is patented, then its status as an approved compound implies it is on the market."
      },
      "(A3 → A4)": {
        "formal": "(A3 → A4)",
        "prover9": "(A3 -> A4)",
        "prover9_expression": "(patented(CompoundX) -> clinical_trial_success(CompoundX))",
        "natural": "If CompoundX is patented, then CompoundX had a successful clinical trial."
      },
      "(A30 ∨ (A29 ∨ (A28 → (¬G → A26))))": {
        "formal": "(A30 ∨ (A29 ∨ (A28 → (¬G → A26))))",
        "prover9": "(A30 | (A29 | (A28 -> (-G -> A26))))",
        "prover9_expression": "(import_license_secured(CompoundX) | (alternative_supplier_found(CompoundX) | (raw_material_shortage(CompoundX) -> (-product_on_market(CompoundX) -> production_delay(CompoundX)))))",
        "natural": "Either an import license was secured for CompoundX, or an alternative supplier was found, or a raw material shortage leads to a production delay when the product is not on the market."
      },
      "(A31 → A21)": {
        "formal": "(A31 → A21)",
        "prover9": "(A31 -> A21)",
        "prover9_expression": "(batch_tracking_system(CompoundX) -> gmp_compliance(CompoundX))",
        "natural": "Under the condition that a batch tracking system is in place for CompoundX, CompoundX is compliant with Good Manufacturing Practices (GMP)."
      },
      "(A32 → (A23 → A31))": {
        "formal": "(A32 → (A23 → A31))",
        "prover9": "(A32 -> (A23 -> A31))",
        "prover9_expression": "(software_implementation(CompoundX) -> (process_automation(CompoundX) -> batch_tracking_system(CompoundX)))",
        "natural": "Provided that software was implemented for CompoundX, then the implementation of process automation necessitates that a batch tracking system is in place."
      },
      "(A32 ∨ A33)": {
        "formal": "(A32 ∨ A33)",
        "prover9": "(A32 | A33)",
        "prover9_expression": "(software_implementation(CompoundX) | hardware_installation(CompoundX))",
        "natural": "Either software was implemented for CompoundX, or hardware was installed for CompoundX."
      },
      "(A33 → (A23 → A31))": {
        "formal": "(A33 → (A23 → A31))",
        "prover9": "(A33 -> (A23 -> A31))",
        "prover9_expression": "(hardware_installation(CompoundX) -> (process_automation(CompoundX) -> batch_tracking_system(CompoundX)))",
        "natural": "Should hardware be installed for CompoundX, then the implementation of process automation implies a batch tracking system is in place."
      },
      "(A34 → A35)": {
        "formal": "(A34 → A35)",
        "prover9": "(A34 -> A35)",
        "prover9_expression": "(system_integration_failure(CompoundX) -> data_corruption(CompoundX))",
        "natural": "Whenever a system integration failure occurred for CompoundX, data corruption occurred for CompoundX."
      },
      "(A34 → A36)": {
        "formal": "(A34 → A36)",
        "prover9": "(A34 -> A36)",
        "prover9_expression": "(system_integration_failure(CompoundX) -> validation_error(CompoundX))",
        "natural": "If a system integration failure occurred for CompoundX, then a validation error occurred for CompoundX."
      },
      "(A34 → ¬A35)": {
        "formal": "(A34 → ¬A35)",
        "prover9": "(A34 -> -A35)",
        "prover9_expression": "(system_integration_failure(CompoundX) -> -data_corruption(CompoundX))",
        "natural": "Provided that a system integration failure occurred for CompoundX, it is not the case that data corruption occurred for CompoundX."
      },
      "(A36 → ¬A35)": {
        "formal": "(A36 → ¬A35)",
        "prover9": "(A36 -> -A35)",
        "prover9_expression": "(validation_error(CompoundX) -> -data_corruption(CompoundX))",
        "natural": "Under the condition that a validation error occurred for CompoundX, data corruption did not occur for CompoundX."
      },
      "(A38 ∨ (A27 → (¬G → A26)))": {
        "formal": "(A38 ∨ (A27 → (¬G → A26)))",
        "prover9": "(A38 | (A27 -> (-G -> A26)))",
        "prover9_expression": "(backup_supplier_available(CompoundX) | (supply_chain_disruption(CompoundX) -> (-product_on_market(CompoundX) -> production_delay(CompoundX))))",
        "natural": "Either a backup supplier is available for CompoundX, or a supply chain disruption implies a production delay when the product is not on the market."
      },
      "(A39 → (A38 ∨ (A27 → (¬G → A26))))": {
        "formal": "(A39 → (A38 ∨ (A27 → (¬G → A26))))",
        "prover9": "(A39 -> (A38 | (A27 -> (-G -> A26))))",
        "prover9_expression": "(contingency_plan_activated(CompoundX) -> (backup_supplier_available(CompoundX) | (supply_chain_disruption(CompoundX) -> (-product_on_market(CompoundX) -> production_delay(CompoundX)))))",
        "natural": "Should a contingency plan be activated for CompoundX, then either a backup supplier is available, or a supply chain disruption leads to a production delay if the product is not on the market."
      },
      "(A39 ∨ A40)": {
        "formal": "(A39 ∨ A40)",
        "prover9": "(A39 | A40)",
        "prover9_expression": "(contingency_plan_activated(CompoundX) | emergency_protocol_executed(CompoundX))",
        "natural": "Either a contingency plan was activated for CompoundX, or an emergency protocol was executed for CompoundX."
      },
      "(A4 → (A1 → G))": {
        "formal": "(A4 → (A1 → G))",
        "prover9": "(A4 -> (A1 -> G))",
        "prover9_expression": "(clinical_trial_success(CompoundX) -> (approved_compound(CompoundX) -> product_on_market(CompoundX)))",
        "natural": "Provided that CompoundX had a successful clinical trial, then its approval implies it is on the market."
      },
      "(A40 → (A38 ∨ (A27 → (¬G → A26))))": {
        "formal": "(A40 → (A38 ∨ (A27 → (¬G → A26))))",
        "prover9": "(A40 -> (A38 | (A27 -> (-G -> A26))))",
        "prover9_expression": "(emergency_protocol_executed(CompoundX) -> (backup_supplier_available(CompoundX) | (supply_chain_disruption(CompoundX) -> (-product_on_market(CompoundX) -> production_delay(CompoundX)))))",
        "natural": "If an emergency protocol was executed for CompoundX, then either a backup supplier is available, or a supply chain disruption necessitates a production delay when the product is not on the market."
      },
      "(A41 → A39)": {
        "formal": "(A41 → A39)",
        "prover9": "(A41 -> A39)",
        "prover9_expression": "(crisis_management_team(CompoundX) -> contingency_plan_activated(CompoundX))",
        "natural": "Under the condition that a crisis management team was formed for CompoundX, a contingency plan was activated for CompoundX."
      },
      "(A41 → A43)": {
        "formal": "(A41 → A43)",
        "prover9": "(A41 -> A43)",
        "prover9_expression": "(crisis_management_team(CompoundX) -> management_approval(CompoundX))",
        "natural": "Should a crisis management team be formed for CompoundX, management approval was obtained for CompoundX."
      },
      "(A41 ∨ A42)": {
        "formal": "(A41 ∨ A42)",
        "prover9": "(A41 | A42)",
        "prover9_expression": "(crisis_management_team(CompoundX) | emergency_response_unit(CompoundX))",
        "natural": "Either a crisis management team was formed for CompoundX, or an emergency response unit was deployed for CompoundX."
      },
      "(A42 → A40)": {
        "formal": "(A42 → A40)",
        "prover9": "(A42 -> A40)",
        "prover9_expression": "(emergency_response_unit(CompoundX) -> emergency_protocol_executed(CompoundX))",
        "natural": "Provided that an emergency response unit was deployed for CompoundX, an emergency protocol was executed for CompoundX."
      },
      "(A43 → A39)": {
        "formal": "(A43 → A39)",
        "prover9": "(A43 -> A39)",
        "prover9_expression": "(management_approval(CompoundX) -> contingency_plan_activated(CompoundX))",
        "natural": "If management approval was obtained for CompoundX, then a contingency plan was activated for CompoundX."
      },
      "(A43 → A44)": {
        "formal": "(A43 → A44)",
        "prover9": "(A43 -> A44)",
        "prover9_expression": "(management_approval(CompoundX) -> board_authorization(CompoundX))",
        "natural": "Whenever management approval was obtained for CompoundX, board authorization was obtained for CompoundX."
      },
      "(A44 → A39)": {
        "formal": "(A44 → A39)",
        "prover9": "(A44 -> A39)",
        "prover9_expression": "(board_authorization(CompoundX) -> contingency_plan_activated(CompoundX))",
        "natural": "Under the condition that board authorization was obtained for CompoundX, a contingency plan was activated for CompoundX."
      },
      "(A46 ∨ ¬A45)": {
        "formal": "(A46 ∨ ¬A45)",
        "prover9": "(A46 | -A45)",
        "prover9_expression": "(regulatory_approval_received(CompoundX) | -authorization_denied(CompoundX))",
        "natural": "Either regulatory approval was received for CompoundX, or authorization was not denied for CompoundX."
      },
      "(A48 → A26)": {
        "formal": "(A48 → A26)",
        "prover9": "(A48 -> A26)",
        "prover9_expression": "(production_rescheduled(CompoundX) -> production_delay(CompoundX))",
        "natural": "Should production of CompoundX be rescheduled, then production of CompoundX was delayed."
      },
      "(A49 → A48)": {
        "formal": "(A49 → A48)",
        "prover9": "(A49 -> A48)",
        "prover9_expression": "(timeline_adjusted(CompoundX) -> production_rescheduled(CompoundX))",
        "natural": "Provided that the timeline for CompoundX was adjusted, production of CompoundX was rescheduled."
      },
      "(A50 ∨ (A27 → (¬G → A26)))": {
        "formal": "(A50 ∨ (A27 → (¬G → A26)))",
        "prover9": "(A50 | (A27 -> (-G -> A26)))",
        "prover9_expression": "(alternative_process_available(CompoundX) | (supply_chain_disruption(CompoundX) -> (-product_on_market(CompoundX) -> production_delay(CompoundX))))",
        "natural": "Either an alternative process is available for CompoundX, or a supply chain disruption implies a production delay when the product is not on the market."
      },
      "(A51 → A50)": {
        "formal": "(A51 → A50)",
        "prover9": "(A51 -> A50)",
        "prover9_expression": "(process_validation_complete(CompoundX) -> alternative_process_available(CompoundX))",
        "natural": "If process validation is complete for CompoundX, then an alternative process is available for CompoundX."
      },
      "(A51 ∨ A52)": {
        "formal": "(A51 ∨ A52)",
        "prover9": "(A51 | A52)",
        "prover9_expression": "(process_validation_complete(CompoundX) | manual_override_authorized(CompoundX))",
        "natural": "Either process validation is complete for CompoundX, or a manual override was authorized for CompoundX."
      },
      "(A52 → (A27 → (¬G → A26)))": {
        "formal": "(A52 → (A27 → (¬G → A26)))",
        "prover9": "(A52 -> (A27 -> (-G -> A26)))",
        "prover9_expression": "(manual_override_authorized(CompoundX) -> (supply_chain_disruption(CompoundX) -> (-product_on_market(CompoundX) -> production_delay(CompoundX))))",
        "natural": "Under the condition that a manual override was authorized for CompoundX, a supply chain disruption implies a production delay when the product is not on the market."
      },
      "(A52 → A53)": {
        "formal": "(A52 → A53)",
        "prover9": "(A52 -> A53)",
        "prover9_expression": "(manual_override_authorized(CompoundX) -> supervisor_approval(CompoundX))",
        "natural": "Provided that a manual override was authorized for CompoundX, supervisor approval was obtained for CompoundX."
      },
      "(A53 → (A27 → (¬G → A26)))": {
        "formal": "(A53 → (A27 → (¬G → A26)))",
        "prover9": "(A53 -> (A27 -> (-G -> A26)))",
        "prover9_expression": "(supervisor_approval(CompoundX) -> (supply_chain_disruption(CompoundX) -> (-product_on_market(CompoundX) -> production_delay(CompoundX))))",
        "natural": "Should supervisor approval be obtained for CompoundX, then a supply chain disruption leads to a production delay if the product is not on the market."
      },
      "(A6 ∨ ¬A5)": {
        "formal": "(A6 ∨ ¬A5)",
        "prover9": "(A6 | -A5)",
        "prover9_expression": "(market_withdrawal(CompoundX) | -regulatory_rejection(CompoundX))",
        "natural": "Either CompoundX was withdrawn from the market, or it is not the case that CompoundX received a regulatory rejection."
      },
      "(A7 ∨ ¬A6)": {
        "formal": "(A7 ∨ ¬A6)",
        "prover9": "(A7 | -A6)",
        "prover9_expression": "(production_halt(CompoundX) | -market_withdrawal(CompoundX))",
        "natural": "Either production of CompoundX was halted, or CompoundX was not withdrawn from the market."
      },
      "(A8 → G)": {
        "formal": "(A8 → G)",
        "prover9": "(A8 -> G)",
        "prover9_expression": "(manufacturing_license_granted(CompoundX) -> product_on_market(CompoundX))",
        "natural": "If a manufacturing license was granted for CompoundX, then CompoundX is on the market."
      },
      "(¬(A11 → A13) → A14)": {
        "formal": "(¬(A11 → A13) → A14)",
        "prover9": "(-(A11 -> A13) -> A14)",
        "prover9_expression": "(-(safety_issue_reported(CompoundX) -> fda_investigation(CompoundX)) -> product_recall(CompoundX))",
        "natural": "If it is not the case that a reported safety issue leads to an FDA investigation, then a product recall occurred for CompoundX."
      },
      "(¬(A24 → A21) → A25)": {
        "formal": "(¬(A24 → A21) → A25)",
        "prover9": "(-(A24 -> A21) -> A25)",
        "prover9_expression": "(-(quality_control_system(CompoundX) -> gmp_compliance(CompoundX)) -> compliance_failure(CompoundX))",
        "natural": "Provided that it is false that a quality control system implies GMP compliance, then a compliance failure occurred for CompoundX."
      },
      "(¬(A32 ∨ A33) → A34)": {
        "formal": "(¬(A32 ∨ A33) → A34)",
        "prover9": "(-(A32 | A33) -> A34)",
        "prover9_expression": "(-(software_implementation(CompoundX) | hardware_installation(CompoundX)) -> system_integration_failure(CompoundX))",
        "natural": "Under the condition that neither software was implemented nor hardware was installed for CompoundX, a system integration failure occurred for CompoundX."
      },
      "(¬(A34 → A36) → A37)": {
        "formal": "(¬(A34 → A36) → A37)",
        "prover9": "(-(A34 -> A36) -> A37)",
        "prover9_expression": "(-(system_integration_failure(CompoundX) -> validation_error(CompoundX)) -> validation_success(CompoundX))",
        "natural": "If it is not the case that a system integration failure leads to a validation error, then validation was successful for CompoundX."
      },
      "(¬(A34 → A36) → ¬A37)": {
        "formal": "(¬(A34 → A36) → ¬A37)",
        "prover9": "(-(A34 -> A36) -> -A37)",
        "prover9_expression": "(-(system_integration_failure(CompoundX) -> validation_error(CompoundX)) -> -validation_success(CompoundX))",
        "natural": "Should it be false that a system integration failure necessitates a validation error, then validation was not successful for CompoundX."
      },
      "(¬(A4 → (A1 → G)) → A5)": {
        "formal": "(¬(A4 → (A1 → G)) → A5)",
        "prover9": "(-(A4 -> (A1 -> G)) -> A5)",
        "prover9_expression": "(-(clinical_trial_success(CompoundX) -> (approved_compound(CompoundX) -> product_on_market(CompoundX))) -> regulatory_rejection(CompoundX))",
        "natural": "Whenever it is not the case that a successful clinical trial implies approval leads to the product being on the market, then CompoundX received a regulatory rejection."
      },
      "(¬(A43 → A44) → A45)": {
        "formal": "(¬(A43 → A44) → A45)",
        "prover9": "(-(A43 -> A44) -> A45)",
        "prover9_expression": "(-(management_approval(CompoundX) -> board_authorization(CompoundX)) -> authorization_denied(CompoundX))",
        "natural": "Provided that it is false that management approval implies board authorization, then authorization was denied for CompoundX."
      },
      "(¬(A46 ∨ ¬A45) → A47)": {
        "formal": "(¬(A46 ∨ ¬A45) → A47)",
        "prover9": "(-(A46 | -A45) -> A47)",
        "prover9_expression": "(-(regulatory_approval_received(CompoundX) | -authorization_denied(CompoundX)) -> approval_pending(CompoundX))",
        "natural": "If it is not the case that either regulatory approval was received or authorization was not denied, then approval is pending for CompoundX."
      },
      "(¬(A46 ∨ ¬A45) → ¬A47)": {
        "formal": "(¬(A46 ∨ ¬A45) → ¬A47)",
        "prover9": "(-(A46 | -A45) -> -A47)",
        "prover9_expression": "(-(regulatory_approval_received(CompoundX) | -authorization_denied(CompoundX)) -> -approval_pending(CompoundX))",
        "natural": "Under the condition that it is false that regulatory approval was received or authorization was not denied, approval is not pending for CompoundX."
      },
      "(¬(A53 → (A27 → (¬G → A26))) → A54)": {
        "formal": "(¬(A53 → (A27 → (¬G → A26))) → A54)",
        "prover9": "(-(A53 -> (A27 -> (-G -> A26))) -> A54)",
        "prover9_expression": "(-(supervisor_approval(CompoundX) -> (supply_chain_disruption(CompoundX) -> (-product_on_market(CompoundX) -> production_delay(CompoundX)))) -> override_rejected(CompoundX))",
        "natural": "Should it be false that supervisor approval implies a supply chain disruption leads to a production delay when the product is not on the market, then an override was rejected for CompoundX."
      },
      "(¬(A53 → (A27 → (¬G → A26))) → ¬A54)": {
        "formal": "(¬(A53 → (A27 → (¬G → A26))) → ¬A54)",
        "prover9": "(-(A53 -> (A27 -> (-G -> A26))) -> -A54)",
        "prover9_expression": "(-(supervisor_approval(CompoundX) -> (supply_chain_disruption(CompoundX) -> (-product_on_market(CompoundX) -> production_delay(CompoundX)))) -> -override_rejected(CompoundX))",
        "natural": "Provided that it is not the case that supervisor approval necessitates a supply chain disruption causing a production delay without the product on the market, then an override was not rejected for CompoundX."
      },
      "(¬A8 → A10)": {
        "formal": "(¬A8 → A10)",
        "prover9": "(-A8 -> A10)",
        "prover9_expression": "(-manufacturing_license_granted(CompoundX) -> generic_available(CompoundX))",
        "natural": "If a manufacturing license was not granted for CompoundX, then a generic version of CompoundX is available."
      },
      "(¬A8 → A9)": {
        "formal": "(¬A8 → A9)",
        "prover9": "(-A8 -> A9)",
        "prover9_expression": "(-manufacturing_license_granted(CompoundX) -> patent_expired(CompoundX))",
        "natural": "Under the condition that a manufacturing license was not granted for CompoundX, the patent for CompoundX has expired."
      },
      "(¬G → A26)": {
        "formal": "(¬G → A26)",
        "prover9": "(-G -> A26)",
        "prover9_expression": "(-product_on_market(CompoundX) -> production_delay(CompoundX))",
        "natural": "Should CompoundX not be on the market, then production of CompoundX was delayed."
      },
      "(¬G → A48)": {
        "formal": "(¬G → A48)",
        "prover9": "(-G -> A48)",
        "prover9_expression": "(-product_on_market(CompoundX) -> production_rescheduled(CompoundX))",
        "natural": "If CompoundX is not on the market, then production of CompoundX was rescheduled."
      },
      "(¬G → A49)": {
        "formal": "(¬G → A49)",
        "prover9": "(-G -> A49)",
        "prover9_expression": "(-product_on_market(CompoundX) -> timeline_adjusted(CompoundX))",
        "natural": "Provided that CompoundX is not on the market, the timeline for CompoundX was adjusted."
      },
      "(¬G → ¬A26)": {
        "formal": "(¬G → ¬A26)",
        "prover9": "(-G -> -A26)",
        "prover9_expression": "(-product_on_market(CompoundX) -> -production_delay(CompoundX))",
        "natural": "Under the condition that CompoundX is not on the market, it is not the case that production of CompoundX was delayed."
      },
      "A1": {
        "formal": "A1",
        "prover9": "A1",
        "prover9_expression": "approved_compound(CompoundX)",
        "natural": "CompoundX is an approved compound."
      },
      "A15": {
        "formal": "A15",
        "prover9": "A15",
        "prover9_expression": "recall_order_issued(CompoundX)",
        "natural": "A recall order was issued for CompoundX."
      },
      "A16": {
        "formal": "A16",
        "prover9": "A16",
        "prover9_expression": "new_formulation(CompoundX)",
        "natural": "A new formulation of CompoundX exists."
      },
      "A2": {
        "formal": "A2",
        "prover9": "A2",
        "prover9_expression": "developed_by(CompoundX, LabAlpha)",
        "natural": "CompoundX was developed by LabAlpha."
      },
      "A27": {
        "formal": "A27",
        "prover9": "A27",
        "prover9_expression": "supply_chain_disruption(CompoundX)",
        "natural": "A supply chain disruption affected CompoundX."
      },
      "A8": {
        "formal": "A8",
        "prover9": "A8",
        "prover9_expression": "manufacturing_license_granted(CompoundX)",
        "natural": "A manufacturing license was granted for CompoundX."
      },
      "G": {
        "formal": "G",
        "prover9": "G",
        "prover9_expression": "product_on_market(CompoundX)",
        "natural": "CompoundX is on the market."
      },
      "¬A14": {
        "formal": "¬A14",
        "prover9": "-A14",
        "prover9_expression": "-product_recall(CompoundX)",
        "natural": "It is not the case that a product recall occurred for CompoundX."
      },
      "¬A25": {
        "formal": "¬A25",
        "prover9": "-A25",
        "prover9_expression": "-compliance_failure(CompoundX)",
        "natural": "A compliance failure did not occur for CompoundX."
      },
      "¬A29": {
        "formal": "¬A29",
        "prover9": "-A29",
        "prover9_expression": "-alternative_supplier_found(CompoundX)",
        "natural": "An alternative supplier was not found for CompoundX."
      },
      "¬A30": {
        "formal": "¬A30",
        "prover9": "-A30",
        "prover9_expression": "-import_license_secured(CompoundX)",
        "natural": "An import license was not secured for CompoundX."
      },
      "¬A34": {
        "formal": "¬A34",
        "prover9": "-A34",
        "prover9_expression": "-system_integration_failure(CompoundX)",
        "natural": "A system integration failure did not occur for CompoundX."
      },
      "¬A38": {
        "formal": "¬A38",
        "prover9": "-A38",
        "prover9_expression": "-backup_supplier_available(CompoundX)",
        "natural": "A backup supplier is not available for CompoundX."
      },
      "¬A45": {
        "formal": "¬A45",
        "prover9": "-A45",
        "prover9_expression": "-authorization_denied(CompoundX)",
        "natural": "Authorization was not denied for CompoundX."
      },
      "¬A46": {
        "formal": "¬A46",
        "prover9": "-A46",
        "prover9_expression": "-regulatory_approval_received(CompoundX)",
        "natural": "Regulatory approval was not received for CompoundX."
      },
      "¬A5": {
        "formal": "¬A5",
        "prover9": "-A5",
        "prover9_expression": "-regulatory_rejection(CompoundX)",
        "natural": "CompoundX did not receive a regulatory rejection."
      },
      "¬A50": {
        "formal": "¬A50",
        "prover9": "-A50",
        "prover9_expression": "-alternative_process_available(CompoundX)",
        "natural": "An alternative process is not available for CompoundX."
      },
      "¬A6": {
        "formal": "¬A6",
        "prover9": "-A6",
        "prover9_expression": "-market_withdrawal(CompoundX)",
        "natural": "CompoundX was not withdrawn from the market."
      },
      "¬A7": {
        "formal": "¬A7",
        "prover9": "-A7",
        "prover9_expression": "-production_halt(CompoundX)",
        "natural": "Production of CompoundX was not halted."
      },
      "¬A9": {
        "formal": "¬A9",
        "prover9": "-A9",
        "prover9_expression": "-patent_expired(CompoundX)",
        "natural": "The patent for CompoundX has not expired."
      }
    }
  }
}